Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLICLAZIDE Cause Chronic obstructive pulmonary disease? 28 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Chronic obstructive pulmonary disease have been filed in association with GLICLAZIDE. This represents 0.5% of all adverse event reports for GLICLAZIDE.

28
Reports of Chronic obstructive pulmonary disease with GLICLAZIDE
0.5%
of all GLICLAZIDE reports
1
Deaths
17
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From GLICLAZIDE?

Of the 28 reports, 1 (3.6%) resulted in death, 17 (60.7%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLICLAZIDE. However, 28 reports have been filed with the FAERS database.

What Other Side Effects Does GLICLAZIDE Cause?

Hypoglycaemia (756) Nausea (596) Acute kidney injury (553) Drug ineffective (507) Fall (415) Dyspnoea (400) Vomiting (385) Lactic acidosis (373) Malaise (360) Hypertension (351)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which GLICLAZIDE Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

GLICLAZIDE vs GLIMEPIRIDE GLICLAZIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLICLAZIDE vs GLIPIZIDE GLICLAZIDE vs GLIVEC GLICLAZIDE vs GLOFITAMAB

Related Pages

GLICLAZIDE Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease GLICLAZIDE Demographics